Ask AI
ProCE Banner Activity

Opportunities to Improve Prevention, Screening, and Equitable Care of Cervical Cancer: A Call to Action

Clinical Thought

Read this commentary with my thoughts on current best practices and ongoing unmet needs in the prevention, screening, and care of cervical cancer, including some areas where continued education for integrating the latest advances in this disease are warranted.

Released: October 21, 2024

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from GlaxoSmithKline and Merck Sharp & Dohme LLC.

GlaxoSmithKline

Merck Sharp & Dohme, LLC

Partners

Smart Patients

ProCE Banner

Financial Disclosures

Primary Author

Linda R. Duska, MD, MPH

Lawrence Penniston Family Endowed Professor of Women’s Oncology Research
Vice-Chair for Research, Department of Obstetrics and Gynecology
Professor, Gynecologic Oncology
Emily Couric Comprehensive Cancer Center
University of Virginia School of Medicine
Charlottesville, Virginia

Linda R. Duska, MD: researcher (paid to institution): AbbVie, Acrivon, Aduro BioTech, Advaxis, Alkermes, Blueprint, Constellation, Eisai, Genentech/Roche, GSK/Novartis, Immunogen, Inovio, Iovance, Karyopharm, KSQ Therapeutics, Lycera, Merck, Morab, MorphoTek, Naveris, Nurix, OncoQuest, Pfizer, Syndax, Tesaro, Zentalis; data and safety monitoring board/advisor: Aegenus, Daiichi Sankyo, Innovio, Merck, NX Development Corp; speaker: Merck.